ACE and myocardial infarction: Treatment with angiotensin converting enzyme (ACE) inhibitors induces accumulation of bradykinin, reduces plasma angiotensin II levels and decreases plasma plasminogen activator inhibitor-1 (PAI-1), a risk factor for myocardial infarction [76,77].